CD274 and non-small cell lung carcinoma: Results of completed phase II trial testing vopratelimab plus CTLA-4 inhibitor in PD-1/PD-L1 inhibitor evaluated on patients with NSCLC or urothelial cancer are expected (NCT03989362).